Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports

BACKGROUND: Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor. Clinical trials have reported its effectiveness in the treatment of brain metastases from non-small cell lung cancer by overcoming the blood–brain barrier. Gefitinib is generally regarded as a relatively safe age...

Descripción completa

Detalles Bibliográficos
Autores principales: Chonan, Masashi, Narita, Norio, Tominaga, Teiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4698324/
https://www.ncbi.nlm.nih.gov/pubmed/26724810
http://dx.doi.org/10.1186/s13104-015-1834-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4698324/
https://www.ncbi.nlm.nih.gov/pubmed/26724810
http://dx.doi.org/10.1186/s13104-015-1834-0

Ejemplares similares